Darifenacin (Page 6 of 6)
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
Darifenacin
Extended Release
Tablets
7.5 mg*
Cipla 30 Tablets
Darifenacin
Extended Release
Tablets
15 mg*
Cipla 30 Tablets
DARIFENACIN darifenacin hydrobromide tablet, extended release | |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
|
DARIFENACIN darifenacin hydrobromide tablet, extended release | |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
|
Labeler — Cipla USA Inc. (078719707) |
Registrant — Cipla USA Inc. (078719707) |
Establishment | |||
Name | Address | ID/FEI | Operations |
Cipla Ltd. Patalganga unit II | 916940208 | ANALYSIS (69097-431), ANALYSIS (69097-432), LABEL (69097-431), LABEL (69097-432), MANUFACTURE (69097-431), MANUFACTURE (69097-432), PACK (69097-431), PACK (69097-432) |
Revised: 08/2021 Cipla USA Inc.
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.